SERTAD2

Across TCGA pan-cancer cohorts, SERTAD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SERTAD2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SERTAD2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SERTAD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, MESO, and COAD are the cancer types where SERTAD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.930	0.625	.021	14	view →
MESO	DFS	Median	All	0.098	0.366	.039	6	view →
COAD	OS	Median	III,IV	0.239	0.791	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SERTAD2–UCEC (DFS)

Open the UCEC breakdown →